BioPhotas Inc.’s patented biophotonic medical device Celluma has received FDA clearance for six separate indications for use. Celluma — LED technology based on NASA and DARPA research — uses three distinct wavelengths of light energy, modulated with proprietary electronic algorithms to effectively treat a variety of skin, muscle and joint conditions. It has received clearance to treat acne, muscle and joint pain, muscle spasms, arthritis, muscle and joint stiffness, and compromised local blood circulation. LED, or biophotonic, therapy has been scientifically proven in recent clinical trials to noninvasively “re-energize” cellular function in the treatment of many common conditions, restoring the body’s natural ability to heal itself, according to NASA and DARPA research. “Receiving FDA clearance for six separate indications for use is a major milestone for us in the development of our product portfolio and the growth of the company,” said President and CEO Patrick Johnson. “Our goal in developing the Celluma was to create a safe, effective and convenient device that could be used in the home and in a professional medical setting.” BioPhotoas develops devices for health-care providers and consumers to treat a variety of pain, dermatology and musculoskeletal conditions. For more information, visit: www.biophotas.com